To appear in Best of the Brokers, email your research to email@example.com
Panmure Gordon reiterated its “sell” rating on the insurer, due to the fact that its recovery “is taking much longer than anticipated”. The broker also said it thinks consensus forecasts are too high and that they will fall in the next few months leading to share price underperformance.
Numis reiterated its “buy” rating on the pharmaceutical company, after its results which were in line with forecasts. The broker said the underlying trend for the firm’s revenue growth is “strong” and added that it expects this operational performance to continue.